Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454595 · ClinicalTrials.gov registry record
Registry to Measure the Impact of Adding Genomic Testing
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 116
- Enrollment target
NCT02454595: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT02454595 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02454595 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 116 participants
- Enrollment target
Study Summary
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the Prolaris® genomic test and a relative cancer aggressiveness score will be shared with the physician and the patient.
Interventions
- BEHAVIORAL Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-07-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454595
The ClinicalTrials.gov registry entry for NCT02454595 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Registry is the first listed.
NCT02454595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02454595 about?
NCT02454595 is a clinical study titled "Registry to Measure the Impact of Adding Genomic Testing". This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the...
What is the current status of trial NCT02454595?
This trial is currently terminated. The enrollment target is 116 participants. The study started on 2014-11. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT02454595?
The interventions under investigation include: Registry (BEHAVIORAL).
Who is sponsoring clinical trial NCT02454595?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.